Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster ...
Krystal Biotech is rated a buy after a strong Vyjuvek launch, but the current valuation reflects premium margins and aggressive global expansion projections. Vyjuvek's US sales growth has plateaued, ...
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results